About the Meeting
About the Meeting:
- When: Tuesday October 30th and Wednesday October 31, 2018
- Where: Basel, Switzerland
- Who: BIO members engaged in the conduct and reporting of preclinical safety evaluations for biopharmaceuticals.
- Registration: This meeting is open to BIO member company staff engaged in the conduct and reporting of preclinical safety evaluation for biopharmaceuticals. Registration is not limited to BioSafe members, but your company must be a member of BIO. Registration details will be available shortly.
The mission of BioSafe is to serve as a resource for BIO members and BIO staff by identifying and responding to key scientific and regulatory issues related to the preclinical safety evaluation of biopharmaceutical products.
The General Membership consists of over 30 companies who work on white papers, responses to regulatory guidance, and expert topic meetings. These companies also make up various expert working groups and ad hoc subcommittees including the Specialty Biologics Expert Working Group, the PK/PD Expert Working Group, ADC Working Group, and Immuno-oncology Task Force.
BioSafe is a committee within BIO's Health Section, comprised of BIO members working to identify key scientific and regulatory issues and developments related to the preclinical safety evaluation of biopharmaceutical products and recommending appropriate science-based responses.